
Two technologies, many advantages
Explore relevant breast cancer targets
-
Reliably test PIK3CA mutations
Interested in actionable PIK3CA mutations in breast cancer? Detect the mutations with confidence.
-
DNA repair status is relevantLearn how our homologous recombination repair (HRR) panel will expand your biomarker coverage beyond BRCA1/2.
-
Comprehensive tumor profilingThe QIAseq Pan-cancer Multimodal Panel allows simultaneous profiling of DNA variants and RNA fusions.
References
1. https://www.who.int/news-room/fact-sheets/detail/breast-cancer. Accessed: Sept 13, 2021.
2. Litton, J.K., Burstein, H.J., Turner, N.C. (2019) Molecular Testing in Breast Cancer. Am Soc Clin Oncol Educ Book. 2019 Jan;39:e1-e7. doi: 10.1200/EDBK_237715.